skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Hello.
Thanks for quality answers to questions.

Would you please help by offering insight to dealing with investor psychology and behaviour; 50% gain in PHM only to now be in the red on this holding?
My current thinking does not make sense to me to hold at the top of a gain only to feel like getting out now that the stock price has declined to the point that it feels like a poor investment decision.
I have been drawn into more aggressive type investments being connected to this subscription (beyond normal style) so I believe I can benefit from your experience and comments about dealing with volatility of the nature in this question.
Thanks
Dave

Read Answer Asked by David on January 29, 2016
Q: Re your answer is insider buying not worthy of a comment?
Read Answer Asked by j stuart on January 29, 2016
Q: i have been noticing a fairly large uptick in volume on knight over the last few days or weeks,normally it trades around 100k a day, but lately much more, maybe your bloomberg terminal give you more info than i can see.
also healthcare stocks across the board are selling off, concordia, knight, phm and even large biotechs in u.s. is this all because of hilary and u.s. election or something else. dave
Read Answer Asked by david on January 29, 2016
Q: Thoughts on CXR looking very attractively priced at the moment? They've got enough international exposure to their business that any action in the US to lower drug prices (which would likely take a new government and years to pass legislation) would not have a significant impact on CXR's business. Clinton's new video against Valeant and people panicking and selling CXR seem to be providing a great entry point.
Read Answer Asked by Arneh on January 29, 2016
Q: Many doctors are enthusiastic about GILD's hepatitis-C treatment which, while very, very expensive, is medically unusual for the high proportion of patients it actually cures (versus, many drug therapies are only incremental improvements on the therapies they supercede.) However - and aside from understandable friction over cost - is GILD potentially the victim of its drug's success: the more people they cure, the fewer customers they have remaining? And unlike, say, Apple (who is running out of new customers but can sell old customers an upgrade), cured patients have no reason to come back for more.
Read Answer Asked by John on January 28, 2016
Q: What are your thoughts on today's earnings? The market seems rather unimpressed.
Read Answer Asked by Brent on January 28, 2016
Q: I know its early yet but I would appreciate your researched insight into this game changing medical process and its potential as an investment.
Read Answer Asked by Ryczard on January 28, 2016
Q: i have been reading that beacon lowered the price target to a $1 and also i read about medicare reimbursement cuts which can negatively impact PHM ? Do you think PHM is still worth holding or should it be sold? What are your thoughts on this company?
Read Answer Asked by steven on January 27, 2016
Q: Hello, in your answer on inspiras earnings today you didn't mention anything about the reverse stock split. I thought this was very bad news. I've never seen a company do a reverse split and not go under. Would like your opinion on this.
Read Answer Asked by Carla on January 26, 2016
Q: Convelo's quarter looks good to me. Could you please comment on the financials and the new CEO. Do you have any data on him? Is this a positive or status quo. Thank You
PS My sister recently compared the price of crude to a bucket of KFC. She told me that there is a thread going around social media that is also doing the comparison. The bucket of chicken was trading at a higher level for a bit last week. What do you think has more value? Please only deduct one question. You do not need to answer the second one but I am curious? Also please ignore if you have already answered another client on the same subject.
Read Answer Asked by Jeremy on January 26, 2016
Q: knight did another deal yesterday, and the way goodman structures it , it seems brilliant.
but the stock cannot get any traction. can you comment on the stock and the deal. dave
Read Answer Asked by david on January 26, 2016
Q: Could you please comment on Convalo's latest release on quarterly earnings.
Read Answer Asked by Shane on January 26, 2016
Q: Recent downturn the health stocks went down farther than the average other groups. In fact, CXR went from $57 to $38. Now with this rebound, the health stocks seem to be lagging including CXR. On my I-Trade account, the most recent update with CXR in January, they have it listed as a sell. Prior to that, they had it listed as a buy. Do you know why this stock is underperforming considering it's been a pick of BNN several times and is in your model portfolio?

Thank you. Your answer will be well appreciated as I have a fair amount of CXR.

Dennis
Read Answer Asked by Dennis on January 25, 2016
Q: Hi,
What do you think about the above us stock?
Good to buy ?
Thanks
Read Answer Asked by Adam on January 22, 2016
Q: Hello Peter et al,

Savaria (SIS) has announced preliminary Q4 info with Revenue up 24% and EBITA up about 40%. Full Q4 and annual results will be released about Mar 10. Questions:
1. They reported in Q3 that 54% of their revenue is from the US which is great. Is there any info on what percentage of their costs are in Canadian dollars as opposed to US dollars or Chinese RMB (which has only decreased about 5% vs the US dollar in the past year).
2. Any guess on how the EBITA increase will shake down to the bottom line? Note, TDDI shows estimated Q4 earnings of .06, same as Q4 2014, which seems a bit light.
3. Would it be reasonable to go above a 3% portfolio weight in SIS, or would you sit in the weeds given the market conditions? Note: our other industrial holdings are BAD 4.6%, TFI 3.1%, and WSP 5.8%.
Many thanks.
Read Answer Asked by Robert on January 21, 2016
Q: NTB is positive on a down day. How do you feel about the prospects for this company? Could the worse be behind them now and new management finally on track to deliver? Insiders seem to think so stepping up to the plate this past week. Is this a buy now?

Thank you
Read Answer Asked by Douglas on January 21, 2016